|
1
|
Harris JR: Fifty years of progress in
radiation therapy for breast cancer. Am Soc Clin Oncol Educ Book.
21–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Danforth DN Jr, Zujewski J, O'Shaughnessy
J, Riseberg D, Steinberg SM, McAtee N, Noone M, Chow C, Chaudhry U,
Lippman M, et al: Selection of local therapy after neoadjuvant
chemotherapy in patients with Stage IIIA, B breast cancer. Ann Surg
Oncol. 5:150–158. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hu XC, Zhang J, Xu BH, Cai L, Ragaz J,
Wang ZH, Wang BY, Teng YE, Tong ZS, Pan YY, et al: Cisplatin plus
gemcitabine versus paclitaxel plus gemcitabine as first-line
therapy for metastatic triple-negative breast cancer (CBCSG006): A
randomized, open-label, multicenter, phase 3 trial. Lancet Oncol.
16:436–446. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Karasawa K, Saito M, Hirowatari H, Izawa
H, Furuya T, Ozawa S, Ito K, Suzuki T and Mitsuhashi N: The role of
chemoradiotherapy in patients with unresectable T4 breast tumors.
Breast Cancer. 20:254–261. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yin Y, Zhang P, Xu BH, Zhang BL, Li Q,
Yuan P, Cai RG, Wang JY, Wang X and Xu XZ: Unfavorable pathological
complete response rate of neoadjuvant chemotherapy epirubicin plus
taxanes for locally advanced triple-negative breast cancer. J
Huazhong Univ Sci Technolog Med Sci. 33:262–265. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shaughnessy JN, Meena RA, Dunlap NE, Jain
D, Riley EC, Quillo AR and Dragun AE: Efficacy of concurrent
chemoradiotherapy for patients with locally recurrent or advanced
inoperable breast cancer. Clin Breast Cancer. 15:135–142. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bollet MA, Sigal-Zafrani B, Gambotti L,
Extra JM, Meunier M, Nos C, Dendale R, Campana F, Kirova YM, Diéras
V, et al: Pathological response to preoperative concurrent
chemo-radiotherapy for breast cancer: Results of a phase II study.
Eur J Cancer. 42:2286–2295. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Matuschek C, Bölke E, Roth SL, Orth K,
Lang I, Bojar H, Janni JW, Audretsch W, Nestle-Kraemling C,
Lammering G, et al: Long-term outcome after neoadjuvant
radiochemotherapy in locally advanced noninflammatory breast cancer
and predictive factors for a pathologic complete remission: Results
of a multivariate analysis. Strahlenther Onkol. 188:777–781. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Niibe Y, Kuranami M, Matsunaga K, Takaya
M, Kakita S, Hara T, Sekiguchi K, Watanabe M and Hayakawa K: Value
of high-dose radiation therapy for isolated osseous metastasis in
breast cancer in terms of oligo-recurrence. Anticancer Res.
28:3929–3932. 2008.PubMed/NCBI
|
|
10
|
Niibe Y and Hayakawa K: Oligometastases
and oligo-recurrence: The new era of cancer therapy. Jpn J Clin
Oncol. 40:107–111. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Milano MT, Zhang H, Metcalfe SK, Muhs AG
and Okunieff P: Oligometastatic breast cancer treated with
curative-intent stereotactic body radiation therapy. Breast Cancer
Res Treat. 115:601–608. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Genet D, Lejeune C, Bonnier P, Aubard Y,
Venat-Bouvet L, Adjadj DJ, Martin J, Labourey JL, Benyoub A,
Clavère P, et al: Concomitant intensive chemoradiotherapy induction
in non-metastatic inflammatory breast cancer: Long-term follow-up.
Br J Cancer. 97:883–887. 2007.PubMed/NCBI
|
|
13
|
Mukai H, Watanabe T, Mitsumori M, Tsuda H,
Nakamura S, Masuda N, Yamamoto N, Shibata T, Sato A, Iwata H and
Aogi K: Final results of a safety and efficacy trial of
preoperative sequential chemoradiation therapy for the nonsurgical
treatment of early breast cancer: Japan Clinical Oncology Group
Study JCOG0306. Oncology. 85:336–341. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Salmon R, Garbey M, Moore LW and Bass BL:
Interrogating a multifactorial model of breast conserving therapy
with clinical data. PLoS One. 10:e01250062015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Massa M, Meszaros P, Baldelli I, Bisso N
and Franchelli S: Aesthetic evaluation in oncoplastic and
conservative breast surgery: A comparative analysis. Plast Reconstr
Surg Glob Open. 3:e3392015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ogawa Y, Kubota K, Ue H, Tadokoro M,
Matsui R, Yamanishi T, Hamada N, Kariya S, Nishioka A, Nakajima H,
et al: Safety and effectiveness of a new enzyme-targeting
radiosensitization treatment (KORTUC II) for intratumoral injection
for low-LET radioresistant tumors. Int J Oncol. 39:553–560.
2011.PubMed/NCBI
|
|
17
|
Tsuzuki A, Ogawa Y, Kubota K, Tokuhiro S,
Akima R, Yaogawa S, Itoh K, Yamada Y, Sasaki T, Onogawa M, et al:
Evaluation of changes in tumor shadows and microcalcifications on
mammography following KORTUC II, a new radiosensitization treatment
without any surgical procedure for elderly patients with stage I
and II breast cancer. Cancers (Basel). 3:3496–3505. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Aoyama N, Ogawa Y, Kubota K, Ohgi K,
Kataoka Y, Miyatake K, Tadokoro M, Yamanishi T, Ohnishi T, Hamada
N, et al: Therapeutic response to a new enzyme-targeting
radiosensitization treatment (KORTUC-SC) for patients with
chemotherapy-resistant supraclavicular lymph node metastasis. J
Cancer Res Ther. 1:215–219. 2013. View Article : Google Scholar
|
|
19
|
Aoyama N, Ogawa Y, Yasuoka M, Takahashi M,
Iwasa H, Miyatake K, Yamanishi T, Hamada N, Tamura T, Nishioka A
and Yamagami T: Therapeutic response to a novel enzyme-targeting
radiosensitization treatment (Kochi Oxydol-Radiation Therapy for
Unresectable Carcinomas) in patients with recurrent breast cancer.
Oncol Lett. 12:29–34. 2016.PubMed/NCBI
|
|
20
|
Aoyama N, Ogawa Y, Yasuoka M, Iwasa H,
Miyatake K, Yoshimatsu R, Yamanishi T, Hamada N, Tamura T,
Kobayashi K, et al: Therapeutic response to a novel
enzyme-targeting radiosensitization treatment (KORTUC II) for
residual lesions in patients with stage IV primary breast cancer,
following induction chemotherapy with epirubicin and
cyclophosphamide or taxane. Oncol Lett. 13:69–76. 2017.PubMed/NCBI
|
|
21
|
Ogawa Y, Kubota K, Ue H, Nishioka A,
Kariya S, Yokota N, Sasaki T, Suzuki K, Nakatani K, Yamanishi T, et
al: Development and clinical application of a new radiosensitizer
containing hydrogen peroxide and hyaluronic acid sodium for topical
tumor injection-a new enzyme-targeting radiosensitization
treatment, KORTUC II (Kochi Oxydol-Radiation Therapy for
Unresectable Carcinomas, Type II). Strahlenther Onkol. 183:100–101.
2007.
|
|
22
|
Ogawa Y, Ue H, Tsuzuki K, Tadokoro M,
Miyatake K, Sasaki T, Yokota N, Hamada N, Kariya S, Hitomi J, et
al: New radiosensitization treatment (KORTUC I) using hydrogen
peroxide solution-soaked gauze bolus for unresectable and
superficially exposed neoplasms. Oncol Rep. 19:1389–1394.
2008.PubMed/NCBI
|
|
23
|
Ogawa Y, Kubota K, Ue H, Kataoka Y,
Tadokoro M, Miyatake K, Tsuzuki K, Yamanishi T, Itoh S, Hitomi J,
et al: Phase I study of a new radiosensitizer containing hydrogen
peroxide and sodium hyaluronate for topical tumor injection: A new
enzyme-targeting radiosensitization treatment, kochi
oxydol-radiation therapy for unresectable carcinomas, Type II
(KORTUC II). Int J Oncol. 34:609–618. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Miyatake K, Kubota K, Ogawa Y, Hamada N,
Murata Y and Nishioka A: Non-surgical care for locally advanced
breast cancer: Radiologically assessed therapeutic outcome of a
new-enzyme-targeting radiosensitization treatment, Kochi
oxydol-radiation therapy for unresectable carcinomas, type II
(KORTUC II) with systemic chemotherapy. Oncol Rep. 24:1161–1168.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tokuhiro S, Ogawa Y, Tsuzuki K, Akima R,
Ue H, Kariya S and Nishioka A: Development of a novel
enzyme-targeting radiosensitizer (KORTUC) containing hydrogen
peroxide for intratumoral injection for patients with low linear
energy transfer-radioresistant neoplasms. Oncol Lett. 1:1025–1028.
2010.PubMed/NCBI
|
|
26
|
Hitomi J, Kubota K, Ogawa Y, Hamada N,
Murata Y and Nishioka A: Non-surgical therapy and radiologic
assessment of stage I breast cancer treatment with novel
enzyme-targeting radiosensitization: Kochi Oxydol-radiation therapy
for unresectable carcinomas, type II (KORTUC II). Exp Ther Med.
1:769–775. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gnant M, Thomssen C and Harbeck N: St.
Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion.
Breast Care (Basel). 10:124–130. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
EORTC Breast Cancer Cooperative Group;
EORTC Radiotherapy Group; Bijker N, Meijnen P, Peterse JL, Bogaerts
J, van Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, et al:
Breast-conserving treatment with or without radiotherapy in ductal
carcinoma-in-situ: Ten-year results of European Organisation for
research and treatment of cancer randomized phase III trial 10853-a
study by the EORTC breast cancer cooperative group and EORTC
radiotherapy group. J Clin Oncol. 24:3381–3387. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG); Darby S, McGale P, Correa C, Taylor
C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, et al:
Effect of radiotherapy after breast-conserving surgery on 10-year
recurrence and 15-year breast cancer death: meta-analysis of
individual patient data for 10,801 women in 17 randomised trials.
Lancet. 378:1707–1716. 2011. View Article : Google Scholar : PubMed/NCBI
|
